NeuroSense Therapeutics, Ltd. (Nasdaq:NRSN), an Israel-based clinical-stage biotechnology company, announced on Monday that it has entered into a collaboration agreement with Dr Ghazaleh Sadri-Vakili, MS, PhD and Massachusetts General Hospital's NeuroEpigenetics Lab.
The collaboration agreement has been signed to explore the neurotherapeutic impact of NeuroSense Therapeutics' lead combination drug, PrimeC, using a novel in vitro model generated from post-mortem ALS brain tissue (synaptoneurosomes (SNs) system).
The objective of the collaborative studies is to expand the understanding of PrimeC's mechanism of action in attenuating ALS-related pathology, specifically TDP-43 accumulation, autophagy defects, mitochondrial dysfunction, and oxidative stress. To address this, ALS- or control-SNs derived from post-mortem brains will be used to treat SH-SY5Y cells to induce reactive oxygen species and mitochondrial dysfunction, as previously shown by the Sadri-Vakili lab, in the presence or absence of PrimeC. Importantly, the studies will compare the potential therapeutic effect of PrimeC combination therapy relative to each one of its FDA-approved compounds, ciprofloxacin and celecoxib, separately, to further demonstrate the beneficial synergistic effect of PrimeC as a combination therapy.
Preliminary results from this collaboration will be presented by Dr Zimri in her talk at the upcoming AD/PD 2023 Advances in Science & Therapy Conference on 28 March - 1 April 2023 in Gothenburg, Sweden.
AbbVie's ELAHERE receives full US FDA approval
Johnson & Johnson's OPSYNVI receives US FDA approval
Outlook Therapeutics receives positive CHMP opinion for ONS-5010 in wet AMD treatment
Human Immunology Biosciences receives ODD from FDA for felzartamab
Eton Pharmaceuticals acquires PKU GOLIKE, expanding rare disease portfolio
Vertex receives FDA clearance for VX-407 Investigational New Drug Application for ADPKD
Phanes Therapeutics receives FDA Fast Track designation for PT886
Bio-Thera Solutions signs new licensing agreement with SteinCares
FDA accepts resubmission of Citius Pharmaceuticals, Inc's BLA for LYMPHIR
GSK Plc reports positive Phase III Jemperli data for endometrial cancer
ImmVira receives FDA Fast Track designation for MVR-T3011 IT